+1 (888) 794-0077
« Return
female scientist in lab

White Paper: Managing the Increasing Demands for Scientific Resources During the COVID-19 Pandemic

As our partners’ research and development programs begin to ramp up, so does the need for additional resources. At WuXi AppTec, we remain committed to ensuring the availability and integrity of the research models used on our customers’ vital development programs is maintained—all while ensuring steps are being taken in compliance with disease control guidelines pertaining to COVID-19.

Find out more about how WuXi AppTec is conducting scientific research in a COVID-19 world, providing quality testing support, keeping compounds in China and continuing to move programs forward with a healthy supply of research models.

Receive a copy of our white paper “Conducting Scientific Research in a COVID-19 World: Meeting the Demand for Animal Models”

Related Articles

Bioanalytical Strategies for Evaluating Immunogenicity in Next-Generation AAV Therapies

Bioanalytical Strategies for Evaluating Immunogenicity in Next-Generation AAV Therapies

Next-generation AAV (adeno-associated virus) therapies have recently emerged as a significant area of therapeutic innovation to address complex or inherited diseases. They offer a potential pathway to treat conditions once deemed untreatable through methods like replacement, inactivation, or introduction of new materials. Viral vectors are essential for delivering these advanced therapies, as they efficiently transport therapeutic material into target cells. Once inside the cell, the vector incorporates into the host’s natural machinery, enabling protein expression and facilitating treatment outcomes.

Advancing Oligonucleotide Drug Development with Ligand Binding Assays in the Preclinical Stage

Advancing Oligonucleotide Drug Development with Ligand Binding Assays in the Preclinical Stage

The development of oligonucleotide drugs has seen remarkable progress, driven by innovations in chemical modifications and delivery systems. These advancements have significantly enhanced drug stability, extended half-life, and improved targeting capabilities, increasing therapeutic efficacy and reducing dosage frequency. However, these benefits come with unique challenges in preclinical bioanalysis, particularly in pharmacokinetics (PK), drug metabolism, and tissue distribution studies.